Category Archives: Immunology

of T, international researchers focus on ‘surprisingly high’ incidence of chronic pain in adolescents – News@UofT

An international research collaboration has been awarded a $9-million research grant from the U.S. National Institutes of Health to tackle the complex problem of chronic musculoskeletal pain in adolescents.

The five-year research project, involving two distinct phases and an international team of researchers from the University of Toronto, the Hospital for Sick Children, Stanford University and Cincinnati Childrens Hospital, will work towards uncovering a biological signature for chronic pain, helping those for whom traditional therapies arent effective.

International in scope and global in its potential impact, the project represents an unprecedented opportunity to perform vital research on a largely unstudied population.

This is the first pediatric study of this magnitude, says project co-investigator Jennifer Stinson, professor in U of Ts Lawrence S. Bloomberg Faculty of Nursing and a nurse practitioner at the chronic pain clinic at the Hospital for Sick Children.

The study will shed light on a phenomenon not well understood. Up to five per cent of adolescents thats 3.5 million in the U.S. alone suffer from chronic musculoskeletal pain. The pain can stem from anything from injuries to juvenile fibromyalgia and Ehlers-Danlos Syndrome, a condition affecting connective tissues in the body.

Childrens chronic pain is really, really underappreciatedin that the incidence of it is surprisingly high, but the awareness of it is surprisingly low, says co-investigator Robert Coghill, director of the Center for Understanding Pediatric Pain and professor of pediatrics at Cincinnati Childrens Hospital Medical Center.

Not all pain is the same, though: A staggering 40 to 60 per cent of sufferers will be considered treatment-resistant. Those adolescents quickly grow into adults with chronic, untreatable pain. But by looking at chronic pain through an array of angles brain imaging, quantitative sensory testing, immunology and psychology the researchers hope to pinpoint which adolescents will or wont respond to treatments, and what underlying factors may be at work in those outcomes.

The first phase of the project will gather these types of data from 250 adolescents aged 14 to 18 who suffer from chronic musculoskeletal pain.

if we are able to capture enough measures across a whole slew of domains, we can then use unbiased machine learning and [big data] algorithms to predict whether patients will respond to treatment or not, explains Massieh Moayedi, assistant professor at U of Ts Faculty of Dentistry, a co-investigator who brings expertise in pain and brain imaging to the project.

A multimodal biomarker will allow us to classify those who are at high risk for pain persistence.

If successful at pinpointing a chronic pain signature, a second phase of the study will commencein which data from a second cohort of 125 adolescent recruits will help validate the pain signature.

This project is really unique, says Stinson, who also leads the iOuch lab at Sick Kids. If we can actually find this biological signature, we have a chance to do more precision medicine based on the phenotype of that child. Well be able to better tailor treatment.

Laura Simons, a psychologist and associate professor at Stanford University with expertise in psychological factors influencing childrens pain, will lead the study.

Im very excited about the immune profiling, says Simons, pointing to a burgeoning field of study that looks at the behaviour of immune cells after trauma or medical interventions such as surgery.

Equally, Simons is curious to see whether some of our pen and pencil measures [of psychology] will rise to the top, to see whether they are as informative as more invasive measures.

While each of the teams will perform their series of tests on their adolescent recruits, Stanford University and the Stanford University Medical Centre will additionally collate data and perform data analysis on the results. The data will remain at Stanford, where the researchers will begin collating one of the worlds largest biobanks of multimodal paediatric pain data for future studies.

Patient recruitment for phase one of the study begins as early as this month.

Go here to see the original:
of T, international researchers focus on 'surprisingly high' incidence of chronic pain in adolescents - News@UofT

Single dose of antibody-based treatment can beat HIV in newborn babies – News-Medical.net

A single dose of an antibody-based treatment can prevent HIV transmission from mother to baby, new nonhuman primate research suggests for the first time. The findings are being published in the journal Nature Communications.

When that single dose is given is key, however. The study found rhesus macaque newborns did not develop the monkey form of HIV, called SHIV, when they received a combination of two antibodies 30 hours after being exposed to the virus.

Delaying treatment until 48 hours, on the other hand, resulted in half of the baby macaques developing SHIV when they were given four smaller doses of the same antibody cocktail. In comparison, the study found macaques that received the current standard HIV treatment - antiretroviral drugs - remained SHIV-free when they started a three-week regimen of that therapy 48 hours after exposure.

These promising findings could mean babies born to HIV-positive mothers can still beat HIV with less treatment."

Nancy Haigwood, Ph.D., study's corresponding's author, professor of pathobiology and immunology in the Oregon Health & Science University School of Medicine, as well as the director at the Oregon National Primate Research Center at OHSU

This is the first time a single dose of broadly neutralizing antibodies given after viral exposure has been found to prevent SHIV infection in nonhuman primate newborns. Previous research by Haigwood, Ann Hessell, Ph.D., and others showed four doses of antibodies started 24 hours after exposure prevented SHIV infection, with all 10 of the baby primates in that study not having any SHIV virus for six months. Both studies used a combination of two antibodies called PGT121 and VRC07-523.

The new study also suggests a much shorter course of antiretroviral therapy given after virus exposure could prevent HIV transmission to newborns. Human babies born from HIV-positive mothers typically take the drug cocktail - a personalized regimen of multiple drugs taken daily - for about six weeks before being re-tested. If the tests are then positive, they likely need to take HIV drugs for the rest of their lives. But this study showed nonhuman primate newborns didn't have SHIV after undergoing antiretroviral therapy for just three weeks starting 48 hours after exposure.

HIV-positive women typically take antiretroviral therapy drugs during pregnancy for their own health, as well as to prevent passing the virus onto their developing child. But mother-to-baby transmission sometimes still happens. Children born to HIV-positive mothers also are given antiretroviral therapy to further prevent infection. However, this drug cocktail can have many negative side effects, involves making special liquid formulations for newborns, and researchers worry about antiretroviral therapy's long-term consequences for development.

Antibodies, however, aren't toxic and can be modified to last a long time in the body, which reduces treatment frequency. This has led researchers to explore their potential to replace or supplement antiretroviral therapy for newborns with HIV-positive mothers as well as for HIV-positive adults.

Next, Haigwood and colleagues plan to see if different antibodies, or a combination of antibodies and antiretroviral therapy, could be even more effective. They also want to determine if the antibodies they evaluate actually eliminate HIV, or only prevent it from replicating.

The research team has regularly shared their primate research findings with the scientific community, including those involved in the International Maternal Pediatric Adolescent AIDS Clinical Trials Network, which is currently leading two trials evaluating a single antibody to treat HIV-exposed newborns.

Source:

Journal reference:

Shapiro, M.B., et al. (2020) Single-dose bNAb cocktail or abbreviated ART post-exposure regimens achieve tight SHIV control without adaptive immunity. Nature Communications. doi.org/10.1038/s41467-019-13972-y.

See the original post here:
Single dose of antibody-based treatment can beat HIV in newborn babies - News-Medical.net

30 babies in Bracknell have missed their vital ‘six in one jabs’ – Bracknell News

DOZENS of Bracknell Forest babies have missed out on important jabs which protect them from potentially deadly illnesses, figures reveal.

The British Society for Immunology has urged the new government to deliver on its promise to develop the UKs first vaccine strategy to protect communities against nasty diseases.

READ THIS: Bad parking - Bracknell News readers send in pictures

Young children should get the so-called six-in-one jab, which protects against six serious infections including polio, whooping cough and diphtheria, in the first few months of their lives.

Public Health England data shows that 30 children in Bracknell Forest who had their first birthday in the six months to September missed out on the vaccination.

But 95.9 per cent of one year olds did have it, meaning the area was above the 95 per cent rate recommended by the World Health Organisation to prevent outbreaks.

The uptake rate for the South East over the period was 93.2 per cent, while the figure across England stood at 92.1 per cent.

The British Society for Immunology said the uptake rate across England for the six-in-one vaccine among one year olds has averaged around 92 per cent over the past year.

ALSO READ: Girls born in Bracknell Forest face more than a dozen years of poor health in old age

Dr Doug Brown, the groups chief executive, said: Low levels of vaccination coverage matter as it means these diseases have the potential to spread within our communities, infecting unvaccinated people, with young babies and people with compromised immune systems particularly at risk.

We urge the new government to deliver on its promise to develop the UKs first vaccine strategy and to fully fund immunisation services to ensure our communities are protected against these preventable diseases.

But he also urged parents to make sure their children get the jabs.

He added: If you are worried your child hasnt received all the doses of the six-in-one vaccine, do make an appointment at your GP surgery.Its much better to get your child vaccinated than risk them catching one of these nasty diseases.

Babies should have three rounds of the six-in-one vaccination at eight, 12 and 16 weeks of age.

READ MORE: Home in Binfield for sale over 1.5 MILLION

It helps them develop a strong immunity to diphtheria, hepatitis B, haemophilus influenza type b, polio, tetanus and whopping cough all described by the NHS as serious childhood diseases.

Nicola Blackwood, Health minister said: Every child must be vaccinated against dangerous and potentially fatal diseases. Vaccine uptake is very high, at around 90 per cent, for most childhood vaccines, but we are determined to drive rates up even further.

"Our new vaccination strategy, published in the new year, will consider a range of approaches to improve uptake.

Read more from the original source:
30 babies in Bracknell have missed their vital 'six in one jabs' - Bracknell News

Invest With A Purpose: Own The Future With Megatrend ETFs – Forbes

We now drive electric cars, watch our favorite shows on mobile devices, attend concerts via virtual reality and control the temperature in our homes by giving instructions to a voice assistant.

Technological innovations like these underpin the transformative forces that are changing how we live and work.

You can harness the growth potential of these powerful forces by investing in megatrend ETFs.

An ETF (exchange-traded fund) is a diversified collection of securities (like a mutual fund) that trades on an exchange (like a stock). Megatrend ETFs capture targeted groups of stocks perceived to be well-positioned to benefit from shifts in technology, society, the environment and demographics over time.

Here's why megatrend ETFs are the next frontier of access and a glimpse at the five megatrends BlackRock sees at the forefront of our changing world.

With megatrend ETFs, iSharesBlackRock's ETF businessoffers individual investors access to opportunities that were once available primarily to institutional investors able to qualify for venture capital, private equity and other private market investments.

This is unlike sector indexes (like Technology or Communications) that more rigidly track companies within a single sector, or broad indexes (like the S&P 500) that track a universe of companies across many industries and are weighted heavily toward larger, more established companies rather than smaller, more disruptive players.

As an example, with megatrend ETFs, investment in the self-driving and electric vehicles trend would go beyond carmakers and also include hardware companies that make road-monitoring sensors, software companies that make the algorithmic "brains" required to guide vehicles as well as battery producers. By looking beyond sectors and regions and selecting companies that are leaders in a particular ecosystem, investors can access the full growth potential underpinning these trends.

Megatrend ETFs are also transparent and easy to own, removing the need to pick single-stock winners, which has proved difficult for investors to successfully do. With the potential to capture long-term growth opportunities, megatrend ETFs can be seen as complementary holdings to your core portfolio.

BlackRock has identified five megatrends shaping our future. Here's a look at each and how they can help position you for tomorrow.

Technology is such a prevalent force that the current era has been dubbed the Fourth Industrial Revolution. How you live and work is shaped by exponential technologies like artificial intelligence, 3D printing and synthetic biology, to name just a few. Technology is driving exponential progress in the tech sector and far beyond and underpins the other megatrends we'll mention shortly.

You can tap into the firms harnessing technology to solve privacy threats by investing in iShares Cybersecurity and Tech ETF.1 The fund seeks to track the investment results of an index composed of companies involved in cybersecurity and technology, including cybersecurity hardware, software, products and services.

Longer lifespans and modern lifestyles will change medicine and consumer habits. If you are fascinated by the possibilities of medical technology, consider ETFs that target companies at the forefront of medical progress. iShares Genomics Immunology and Healthcare ETF2 is one such option. This ETF seeks to track the investment results of an index composed of companies that could benefit from the long-term growth and innovation in personalized medicine: genomics, immunology and bioengineering.

It's expected that more than two-thirds of the world's population will reside in cities by 2050, double the percentage from 1950.3 This mass migration to cities will require new business models and infrastructure.

If you would like to invest in companies that may benefit from this megatrend, consider iShares U.S. Infrastructure ETF.4 The fund seeks to track the investment results of an index composed of equities of U.S. companies that have infrastructure exposure and could benefit from a potential increase in domestic infrastructure activities. This ETF offers access to two groups of infrastructure companies that are equally weighted: owners and operators, such as railroads and utilities, and enablers, such as materials and construction companies.

Demand for a clean, green tomorrow will advance energy and conservation. If you drive, or would like to drive, an electric car, you may be interested in putting your money in an ETF with an environmental focus. iShares Self-Driving EV and Tech ETF5 seeks to track the investment results of an index composed of companies that may benefit from growth and innovation in and around electric vehicles, battery technologies and autonomous driving technologies.

It's expected that the number of newly affluent consumers will expand in Asia and across emerging markets. For example, China now has 3.5 million millionaires and more residents with wealth above $50 million than any country except the United States.6 iShares MSCI China A ETF7 can provide access to the Chinese market as it tracks the investment results of an index composed of domestic Chinese equities that trade on the Shanghai or Shenzhen Stock Exchange and are not well-represented in broad benchmarks.

Every day, you witness how megatrend-driven innovations are transforming our world. With iShares megatrend ETFs, you can invest in the future today.

For more information on how ETFs can help you invest in our changing world, click here.

Carefully consider the Funds' investment objectives, risk factors, and charges and expenses before investing. This and other information can be found in the Funds' prospectuses or, if available, the summary prospectuses, which may be obtained by visiting http://www.iShares.com or http://www.blackrock.com. Read the prospectus carefully before investing.

Investing involves risk, including possible loss of principal.

Read the rest here:
Invest With A Purpose: Own The Future With Megatrend ETFs - Forbes

Immunology Market Share, Revenue, And Average Worth By Makers Shared In An Exceedingly Latest Analysis Report – Expert Recorder

The Immunology market report [5 Years Forecast 2020-2025] focuses on Major Leading Industry Players, providing info like Immunology market competitive situation, product scope, market overview, opportunities, driving force and market risks. Profile the top manufacturers of Immunology, with sales, revenue and global market share of Immunology are analyzed emphatically by landscape contrast and speak to info. Upstream raw materials and instrumentation and downstream demand analysis is additionally administrated. The Immunology market business development trends and selling channels square measure analyzed. From a global perspective, It also represents overall industry size by analyzing qualitative insights and historical data.

The study encompasses profiles of major companies operating in the global Immunology market. Key players profiled in the report includes : AbbVie, Amgen, F. Hoffmann-La Roche, Johnson & Johnson, Bionor Pharma, Celgene, Cellectar Biosciences, eFFECTOR Therapeutics and among others.

Get Free Sample PDF (including full TOC, Tables and Figures) for more Professional and Technical insights @https://www.researchmoz.us/enquiry.php?type=S&repid2040006

This Immunology market report provides a comprehensive analysis of:Industry overview, cost structure analysis, technical data and competitive analysis, topmost players analysis, development trend analysis, overall market overview, regional market analysis, consumers analysis and marketing type analysis.

Scope of Immunology Market:

The global Immunology market is valued at million US$ in 2019 and will reach million US$ by the end of 2025, growing at a CAGR of during 2020-2025. The objectives of this study are to define, segment, and project the size of the Immunology market based on company, product type, application and key regions.

This report studies the global market size of Immunology in key regions like North America, Europe, Asia Pacific, Central & South America and Middle East & Africa, focuses on the consumption of Immunology in these regions.

This research report categorizes the global Immunology market by players/brands, region, type and application. This report also studies the global market status, competition landscape, market share, growth rate, future trends, market drivers, opportunities and challenges, sales channels, distributors, customers, research findings & conclusion, appendix & data source and Porters Five Forces Analysis.

The end users/applications and product categories analysis:

On the basis on the end users/applications,this report focuses on the status and outlook for major applications/end users, sales volume, market share and growth rate of Immunology foreach application, including-

On the basis of product,this report displays the sales volume, revenue (Million USD), product price, Immunology market share and growth rate ofeach type, primarily split into-

Do You Have Any Query Or Specific Requirement? Ask to Our Industry [emailprotected]https://www.researchmoz.us/enquiry.php?type=E&repid2040006

(*Fill the form and our sales representative will get back to you for assistance)

Immunology Market : The Regional analysis covers:

The Crucial Questions Answered by Immunology Market Report:

The report offers exclusive information about the Immunology market, based on thorough research about the macro and microeconomic factors that are instrumental in the development of the market. The information featured in this report can answer salient questions for companies in the Immunology market, in order to make important business-related decisions. Some of these questions include:

And Many More.Contact Us:

ResearchMozMr. Nachiket Ghumare,Tel: +1-518-621-2074USA-Canada Toll Free: 866-997-4948Email: [emailprotected]Follow us on LinkedIn @ http://bit.ly/2RtaFUo

Follow me on : https://marketnews-24.blogspot.com/

Read more:
Immunology Market Share, Revenue, And Average Worth By Makers Shared In An Exceedingly Latest Analysis Report - Expert Recorder

Cytovia Therapeutics and the University of California, San Francisco enter into a partnership to develop precision gene-edited CAR-NK cell therapy -…

SAN FRANCISCO and NEW YORK, Jan. 06, 2020 (GLOBE NEWSWIRE) -- Cytovia Therapeutics, a biopharmaceutical company, and the University of California, San Francisco (UCSF) announced today that they have entered a 3-year research partnership to develop novel precision gene editing to improve the performance, safety and persistence of Natural Killer (NK) cells and Chimeric Antigen Receptor (CAR)-NK cells. The lead investigator is Justin Eyquem, PhD, a Principal Investigator in the Microbiology & Immunology Department at UCSF. Cytovia will have an exclusive option to license certain patentable inventions developed as part of the research program.

Dr Daniel Teper, CEO of Cytovia said: Cytovia is committed to advancing the development of NK biotherapeutics with a primary focus on off the shelf CAR NK cells and multispecific antibodies. The partnership with UCSF will utilize advanced gene editing technology to develop precision CAR NK cell therapeutics for both solid and hematological cancers.

Dr Justin Eyquem, of UCSF added: With their safer profile, their natural antitumor activity through a variety of receptors and their allogeneic potential, NK cells are a great addition to the adoptive therapy field. We strongly believe that precision gene editing and rational CAR design will not only make CAR NK cells stronger and safer, but also greatly standardize their manufacturing.

About Cytovia Therapeutics: Cytovia is dedicated to the development of transformational cancer immunotherapies, addressingseveral of the most challenging unmet medical needsincluding the prevention of cancer relapse and metastasis. Cytovia focuses on Natural Killer (NK) cell biology and applies precision medicine tools to develop the right therapy for the right patientat the right stage of the disease. Cytovia has secured access to multiple advanced technologies, including allogeneic cell therapy, multispecific antibodies, and cytokines.Cytovia establishes development partnerships to accelerate time-to-market and commercialization alliances in order to optimize rapid adoption of its novel immunotherapies.

About UCSF:The University of California, San Francisco (UCSF) is exclusively focused on the health sciences and is dedicated to promoting health worldwidethrough advanced biomedical research, graduate-level education in the life sciences and healthprofessions, and excellence in patient care. It includes UCSF Health, which comprises three top-ranked hospitals, as well as affiliations throughout the Bay Area. Learn more athttps://www.ucsf.edu,or see ourFact Sheet.

Contact information:

CYTOVIA Therapeutics:Anna Baran-DjokovicVP, Corporate Affairsanna@cytoviatx.com

Cytovia Media Contact:Charlotte Tomiccharlotte@tomiccommmunications.comCell 9178825243

UCSF Media:Laura KurtzmanSenior Public Information Officer1-415-476-3163laura.kurtzman@ucsf.edu

The rest is here:
Cytovia Therapeutics and the University of California, San Francisco enter into a partnership to develop precision gene-edited CAR-NK cell therapy -...

HIV-Associated Immune Amnesia Could Explain Why HIV-Positive People Have Shorter Lives – PrecisionVaccinations

A new study led by the Oregon Health & Science University School of Medicine and Oregon National Primate Research Center found Human Immunodeficiency (HIV) patients lose immunity to smallpox, even though they were vaccinated against the disease as children.

Called HIV-associated immune amnesia, this finding published on January 2, 2020, could explain why people living with HIV still tend to have shorter lives on average than their HIV-negative counterparts, despite being on antiretroviral therapy.

This new study was published in the Journal of Infectious Diseases and follows other research recently published in the journals Science and Science Immunology that found the immune systems of children who contracted measles similarly "forgot" their immunity against other illnesses, such as influenza.

The previous study was published on October 31, 2019, found measles infections in children can eliminate the immune systems memory to fight off other illnesses.

That was the first study to show definitive evidence that a measles virus infection can destroy important immune cells that remember previous encounters with specific bacteria.

Led by Mark K. Slifka, Ph.D., a professor of molecular microbiology and immunology at the Oregon Health & Science University School of Medicine and Oregon National Primate Research Center, this new study compared T-cell and antibody responses of a total of 100 HIV-positive and HIV-negative women who were vaccinated against smallpox in their youth.

The research team chose smallpox because its last known U.S. case was in 1949, meaning study subjects haven't recently been exposed to its virus, which would have triggered new T-cell and antibody responses.

They found the immune systems of HIV-positive women who were on antiretroviral therapy had a limited response when their blood was exposed to the vaccina virus, which is used in the smallpox vaccine.

Normally, those vaccinated against smallpox have CD4 T cells that remember the virus and respond in large numbers when they're exposed again. Previous research has shown smallpox virus-specific CD4 T cells are maintained for up to 75 years after vaccination.

This finding happened despite the fact that antiretroviral therapy works by boosting CD4 T cell counts in HIV-positive patients. This indicates that while antiretroviral therapy may boost total T cell counts overall, it can't recover virus-specific T cells generated from prior childhood vaccinations.

Dr. Slifka and his colleagues plan to evaluate whether the same phenomenon occurs in HIV-infected men and if people living with HIV also lose immune memory to other diseases.

Researchers who contributed to this study are affiliated with OHSU, SUNY Downstate, Georgetown University, Cornell University, University of Southern California and John Hopkins University.

This research was supported by the National Institutes of Health Public Health Service (grant U19 AI109948) and the Oregon National Primate Research Center (grant 8P51 OD011092).

HIV vaccine news published by Precision Vaccinations.

See more here:
HIV-Associated Immune Amnesia Could Explain Why HIV-Positive People Have Shorter Lives - PrecisionVaccinations

Common fruitfly at the centre of global meet in Pune in modern biology – Hindustan Times

PUNE National and international experts from various streams of biology, cancer and DNA damage, immunology and memory formation in the brain have gathered in Pune to discuss deep research into the common fruitfly at the 5th Asia Pacific Drosophila Research Conference (APDRC5) and Indian Drosophila Research Conference that began here today.

Two Nobel laureates, Eric Wieschaus and Michael Rosbash, renowned for their work in development biology and chronobiology respectively, are among the 100 international and 330 Indian participants in this five-day conference, being held in the country for the first time.

Organised by the Indian Institute of Science Education and Research (IISER), Pune, IISERs Professor (Biology) Sutirth Dey said, This meeting is special for us because the Indian scientific community is very strong in Drosophila. This is one of those meetings in which, absolutely, the whos who of drosophoila biology from all over the world are coming. They are not only going to meet other scientists but also the post-doctoral, PhD students and under-graduates, he said.

Dey, who is using Drosophila for research in Ecology and Evolution said this common fruitfly has a very different kind of immune system from humans and yet, some pathways are common.

It has been one of the most widely-used model organism in the world for research in life sciences over the last 100 years because its genome has been entirely sequenced and there is enormous information available about its biochemistry, physiology and behaviour, he said.

The entire process of development from a cell to a full-fledged organism has been studied in Drosophila. Scientists have found that many similarities exist between Drosophila and higher organisms and therefore this research is very useful, said Dey.

One of the highlights of the Pune conference is the participation of under-graduate, post-graduate and PhD students from top institutes across the country. Fifty six under-graduate students from nine institutes across India and 13 students from nine foreign institutes in the US, Japan, China and Taiwan are participating in this conference.

Drosophila brings together a range of experts such as developmental biologists, neurobiologists, evolutionary biologists, molecular biologists and others, all of who discuss their insights into the drosophila system.

Some of the top scientists participating are K Vijayaraghavan, developmental biologist and principal scientific advisor to Government of India, Developmental biologist LS Shashidhara; evolutionary biologist Amitabh Joshi; Subhash Lakhotia, a specialist in Chromosome Biology and Rakesh Mishra, an expert in Genomics and Epigenetics.

Trudi Schupbach, an expert on cancer and DNA damage from Princeton University; Gines Morata, an expert on formation of body patterns and gene functions from Spain; Kenji Matsuno, from Osaka University, and Ann Shyn Chiang, an expert on memory formation in brain from the National Tsing Hua University, Taiwan, are among those participating at the event.

See the rest here:
Common fruitfly at the centre of global meet in Pune in modern biology - Hindustan Times

Trabectedin Targets Leukemic Cells and Restores Immune Cell Function in Models of Chronic Lymphocytic Leukemia – Cancer Therapy Advisor

The marine-derived compound trabectedin depletes both human primary leukemic cells and myeloid-derived suppressor cells, according to a new study published in Cancer Immunology Research.1 The researchers think their findings could lead to a new therapy that targets both leukemic cells and the protumor microenvironment, repairing the immune dysfunction that is characteristic of chronic lymphocytic leukemia (CLL).

CLLis characterized by lymphocyte accumulation in the blood, bone marrow, andlymphoid tissues.2 Recent advances in CLL therapy have come fromfinding and targeting the appropriate molecular pathways of the disease,explained Kanti R. Rai, MD, a professor of medicine and molecular medicine atthe Donald and Barbara Zucker School of Medicine at Hofstra/Northwell whowasnt involved in the study. Dr Rai said that, for instance, the Brutontyrosine kinase inhibitor ibrutinib binds to the receptor and affects B-cellreceptorsignaling. Another drug, venetoclax, an antagonist to BCL2, can effectivelyinduce apoptosis in CLL cells. However, treatment of this disease remainschallenging due to its immunosuppressive nature. If we [are] to attain a cure,newer compounds have to be identified which have a different mechanism ofcontrolling CLL, he said.

Patientswith CLL have dysfunctional T cells, noted Maria Teresa Bertilaccio, PhD, whois an assistant professor in the department of experimental therapeutics at TheUniversity of Texas MD Anderson Cancer Center in Houston, and the correspondingauthor of the study. Patients [with CLL] have immunosuppression features, sothey might develop an infection because their immune system is not working,she told Cancer Therapy Advisor. Our approach is not only to eradicateleukemia, but also to rearm the immune system to give patients a better qualityof life.

Trabectedintargets tumor-associated macrophages (TAMs); TAMs are thought to support CLLgrowth. A previous study by the Bertilaccio group showed that depleting TAMs byblocking CSF1R signaling reprograms the tumor microenvironment toward anantitumor phenotype.3 This led them to hypothesize that trabectedincould simultaneously target both leukemic cells and nonmalignant cells in thetumor microenvironment.

Continued here:
Trabectedin Targets Leukemic Cells and Restores Immune Cell Function in Models of Chronic Lymphocytic Leukemia - Cancer Therapy Advisor

Johnson & Johnson: The Pharma Giant That Continues To Grow – Seeking Alpha

I do not paint a portrait to look like the subject, rather does the person grow to look like his portrait. - Salvador Dali

Johnson & Johnson (NYSE:JNJ), the worlds biggest pharmaceutical company by market cap, has enjoyed a great end to the year after its stock hit a fresh 2019 high of $147.84 in the previous week. Despite the recent litigation, the company is well positioned to continue growing thanks to its impressive pharmaceutical portfolio.

Most recently, the company has faced legal headwinds in the context of its alleged involvement in the opioid crisis. However, the latest test results released by the company show that J&Js baby powder did not contain asbestos. Previously, the U.S. Food and Drug Administration studies showed that the product contained the material.

The tests that were conducted are part of a large-scale effort by J&J to prove the safety of its widely used consumer product after the test by the FDA prompted J&J to undertake a nationwide recall of one lot of Johnsons Baby Powder in October.

A crisis involving baby powder didnt stop the banking titan Barclays to upgrade the JNJ stock from Equal Weight to Overweight.

In our view, litigation concerns are more than priced in and the risk/reward is attractive. We think J&J checks a lot of boxes heading into 2020, leaving risk/reward skewed to the upside. said Kristen Stewart, an analyst at Barclays.

Furthermore, the bank raised the price target to $173. The stock closed yesterday's trading session at $145.30.

This is the second time J&Js stock was upgraded in one week. Previously, Morgan Stanley analyst David Lewis made the same upgrade - from Equal Weight to Overweight, describing the companys stock as an attractive buying opportunity.

Out of 19 analysts covering Johnson & Johnson, 13 have upgraded the stock to either Buy or Overweight.

The upgrades didnt surprise many as the after the company reported in October that Q3 earnings and revenue beat estimates, thanks to growing sales of cancer and other prescription drugs, regardless of multi-million-dollar legal issues the company.

The pharmaceutical giant reported adjusted earnings of $2.12 per share, beating the expected $2.01 per share. The reported revenue was $20.73, again higher than the expected $20.07 billion. Overall, the companys three main components reported better-than-expected results.

Technically, the price is trading just below the all-time high of $148.99, printed in December 2018. The stock has been rallying since the Q3 earnings report was released on October 23, a day after the stock printed a 9-month low of $126.10. In around two months time, JNJ has managed to increase its market cap by around 15%.

The price action is supported by the horizontal support near the $145 mark, the previous 2019 high, and $141.50 where the broken descending trend line that connects two previous lower highs sits.

If the bulls continue to move the price higher, the initial target is the zone around the $150 mark where the 127.2% Fibonacci extensions of the June 19-October 19 correction lower lie. Overall, any move above $149 will mark a new all-time high for shares of JNJ.

As I mentioned in the Lead-Lag Report, the US stock market is well-positioned to continue rising in 2020, hence a future upside is a strong possibility for a healthy businesses such as Johnson & Johnson.

Arguably the biggest strength of the company is portfolio diversification. JNJ continues to impress with its performance in the areas of oncology and immunology, where its products such as Imbruvica, Stelara and Tremfya continue to yield profits. For instance, Tremfyas portfolio increased as much as 69% in the third quarter.

I wouldnt be surprised if the company goes aggressive on the expansion front. It is expected that the growth in the pharmaceutical sector should further pick up in 2020, which should benefit the company given the historical correlation between J&J's stock and pharma growth.

Johnson & Johnson finds itself in a great financial shape as its operations in the healthcare industry are unrivaled. Thanks to the diversified portfolio, especially within the oncology and immunology fields, shares of Johnson & Johnson appear to be a solid investment option as the bulls look determined to push the price north of $150.

*Like this article? Don't forget to hit the follow button above!

How To Avoid the Most Common Trading Mistakes

Sometimes, you might not realize your biggest portfolio risks until its too late.

Thats why its important to pay attention to the right market data, analysis, and insights on a daily basis. Being a passive investor puts you at unnecessary risk. When you stay informed on key signals and indicators, you'll take control of your financial future.

My award-winning market research gives you everything you need to know each day, so you can be ready to act when it matters most.

Click here to gain access and try the Lead-Lag Report FREE for 14 days.

Disclosure: I/we have no positions in any stocks mentioned, and no plans to initiate any positions within the next 72 hours. I wrote this article myself, and it expresses my own opinions. I am not receiving compensation for it (other than from Seeking Alpha). I have no business relationship with any company whose stock is mentioned in this article.

Additional disclosure: This writing is for informational purposes only and Lead-Lag Publishing, LLC undertakes no obligation to update this article even if the opinions expressed change. It does not constitute an offer to sell, a solicitation to buy, or a recommendation regarding any securities transaction. It also does not offer to provide advisory or other services in any jurisdiction. The information contained in this writing should not be construed as financial or investment advice on any subject matter. Lead-Lag Publishing, LLC expressly disclaims all liability in respect to actions taken based on any or all of the information on this writing.

Here is the original post:
Johnson & Johnson: The Pharma Giant That Continues To Grow - Seeking Alpha